HCMHutchmedSigning up patients
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Advanced Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 412 (planned)
- Started
- Dec 12, 2024
- Main results expected
- Jan 8, 2029
- Fully finished
- Jun 9, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as assessed by IRC
Measured over: Up to approximately 4 years
Overall Survival (OS)
Measured over: Up to approximately 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06584032 · record last updated 2025-01-07 · checked 2026-11-09 15:36 UTC